In the article “Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors,” by Pandit-Taskar et al. (J Nucl Med. 2019;60:1794–1801), information for Kim Kramer was inadvertently left out of the Disclosure section. The Disclosure should have additionally stated: Kim Kramer is a paid consultant for Y-mAbs Therapeutics, Inc. The authors regret the error.
In the article “Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer,” by Czernin et al. (J Nucl Med. 2021;62:228–231), the Disclosure section should have included the following information: The study was supported in part by a Broad Stem Cell Research Center (BSCRC) Innovation Award. The authors regret the error.
- © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
